Ipamorelin vs Tesamorelin
Written by the Pure Peptides editorial team
Reviewed by Dr. Martina Rossi, PhD
Scientific Contributor and Reviewer · Reviewed
Published · Updated · 12 references
Ipamorelin and Tesamorelin are different molecules: Ipamorelin is a synthetic five-residue peptide, and Tesamorelin is a synthetic 44-residue analog of human growth hormone-releasing hormone.
Structure at a glance
Ipamorelin · 5 residues
Tesamorelin · 44 residues
Hex: N-terminal trans-3-hexenoyl group. NH2: C-terminal amide. A raised D marks a D-amino acid. 2Nal: 2-naphthylalanine. Aib: alpha-aminoisobutyric acid. Codes are three-letter amino acid codes.
Drawn from the product database. Each measure's bars share one scale.
| Property | Ipamorelin | Tesamorelin |
|---|---|---|
| What it is | A five-residue peptide that does not correspond to any natural peptide sequence. | A 44-residue peptide: an analog of human growth hormone-releasing hormone with an N-terminal trans-3-hexenoyl group. |
| How they relate | Different molecules. Ipamorelin is a synthetic construct that does not correspond to any natural peptide sequence. Tesamorelin is a synthetic analog of the full 44-residue human growth hormone-releasing hormone. | |
| CAS number | 170851-70-4 | 218949-48-5 |
| Molecular formula | C38H49N9O5 | C221H366N72O67S |
| Molecular weight | 711.85 g/mol | 5,135.86 g/mol |
| Sequence | Aib-His-D-2Nal-D-Phe-Lys-NH2 | trans-3-hexenoyl-Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-Gln-Gln-Gly-Glu-Ser-Asn-Gln-Glu-Arg-Gly-Ala-Arg-Ala-Arg-Leu-NH2 |
| Evidence base | Three published human studies. One was a pharmacokinetic-pharmacodynamic study in healthy male volunteers.[1] A randomized phase 2 trial missed its key endpoint and its secondary analyses.[2] The third tracked its breakdown products in one volunteer's urine.[11] | Human studies, which supported an approval for one indication. A pooled analysis of two phase 3 trials covered 806 randomized participants.[3] Their primary endpoints were imaging surrogates. The trial papers were manufacturer-sponsored. |
| Regulatory status | The FDA has not approved Ipamorelin for human use. | The FDA approved tesamorelin acetate in 2010 for one therapeutic indication.[4][5] That approval is current. |
| Compared head-to-head? | No direct comparison found in PubMed (searched October 2026).[6] | |
| Handling difference | Neither contains a cysteine. Ipamorelin contains no sulfur and so no methionine; Tesamorelin contains one methionine, which oxidizes on air exposure. | |
How Ipamorelin and Tesamorelin differ
Ipamorelin and Tesamorelin are different molecules. Ipamorelin is a five-residue peptide, a synthetic construct that does not correspond to any natural peptide sequence. Tesamorelin is a synthetic analog of the full 44-residue human growth hormone-releasing hormone, with a trans-3-hexenoyl group on its N-terminus.
The literature reviewed for Ipamorelin includes three published human studies. One was an early-phase pharmacokinetic-pharmacodynamic study in healthy male volunteers.[1] The other was a randomized phase 2 trial of 114 participants, and it missed its key endpoint and its secondary analyses.[2] The third, a 2015 anti-doping laboratory study, tracked its breakdown products in one volunteer's urine for two days.[11] Almost everything else known about Ipamorelin comes from preclinical pharmacology. The foundational pharmacology study, published in 1998, used rat cells in vitro, anesthetized rats and conscious swine.[7] Much of the defining preclinical work comes from the original developer, which raises the usual question of independent replication. FDA's 2024 review of the phase 2 trial records serious adverse events in 10 of 56 patients given Ipamorelin and 9 of 58 given placebo.[12] Two patients given Ipamorelin died after colon cancer surgery complicated by a leak where the bowel was rejoined.[12] FDA states it is unclear whether the deaths were related to Ipamorelin.[12]
A pooled analysis of Tesamorelin's two phase 3 trials covered 806 randomized participants.[3] In the literature reviewed for Tesamorelin, those trials used imaging surrogates as primary endpoints, not clinical outcomes. The two trial papers and the pooled analysis were manufacturer-sponsored, with sponsor-affiliated co-authors. A randomized phase 2 trial of 73 participants, in another indication, found no significant difference on the measure reported for it.[8] In the first of the two randomized placebo-controlled phase 3 trials, withdrawal because of an adverse event was higher on Tesamorelin than on placebo.[9]
The FDA has not approved Ipamorelin for human use. The FDA approved tesamorelin acetate in 2010 for one therapeutic indication.[4][5] That approval is current, and it belongs to tesamorelin acetate and to that one indication. Tesamorelin acetate is the active ingredient of a prescription medicine sold under another name. The material supplied here is a research-grade preparation, is not that medicine, and holds no marketing authorization. That medicine's label lists glucose intolerance or new diabetes among its warnings; HbA1c reached 6.5% or above in 5% of participants on the drug against 1% on placebo.[10]
Ipamorelin contains no sulfur, so it has no cysteine and no methionine. Tesamorelin's chemical liabilities are ordinary. It contains no cysteine but has a single methionine, which oxidizes to a sulfoxide on air exposure. Its sequence includes asparagine and glutamine, which both deamidate; Ipamorelin contains neither. Ipamorelin's remaining chemical liabilities are general: amide hydrolysis under strong acid or alkali, slow near neutral pH, and oxidation of its aromatic side chains. Tesamorelin may also aggregate on repeated freezing and thawing.
Have Ipamorelin and Tesamorelin been compared directly?
No direct comparison of Ipamorelin with Tesamorelin was found in a PubMed search run in October 2026.[6] That search covers PubMed only.
Read more on each compound
Ipamorelin
Frequently Asked Questions
Is Ipamorelin the same as Tesamorelin?+−
Ipamorelin and Tesamorelin are different molecules. Ipamorelin is a synthetic five-residue peptide that does not correspond to any natural peptide sequence. Tesamorelin is a synthetic analog of the full 44-residue human growth hormone-releasing hormone, with a trans-3-hexenoyl group on its N-terminus.
Is Ipamorelin or Tesamorelin approved?+−
The FDA has not approved Ipamorelin for human use; it approved tesamorelin acetate in 2010 for one therapeutic indication. Tesamorelin acetate is the active ingredient of a prescription medicine sold under another name. The material supplied here is a research-grade preparation, is not that medicine, and holds no marketing authorization.
References
- 1Gobburu JV, Agerso H, Jusko WJ, Ynddal L. Pharm Res. 1999;16(9):1412-6. doi:10.1023/a:1018955126402. PMID 10496658.
- 2Beck DE, Sweeney WB, McCarter MD. 2014;29(12):1527-1534. doi:10.1007/s00384-014-2030-8. PMID 25331030.
- 4US Food and Drug Administration, Center for Drug Evaluation and Research. Approval letter for tesamorelin, 10 November 2010 (Reference ID 2863003).
- 5US Food and Drug Administration, Drugs@FDA. Approval record whose active ingredient is tesamorelin acetate; marketing status Prescription. Retrieved via api.fda.gov/drug/drugsfda.json on products.active_ingredients.name "TESAMORELIN ACETATE", 3 October 2026.
- 6
PubMed search, 3 October 2026 (records to 2 October 2026)
6 records; none was a direct comparison of the two compounds.
Exact query (NCBI E-utilities): ("ipamorelin"[tiab]) AND ("tesamorelin"[tiab]) AND ("1800/01/01"[edat] : "2026/10/02"[edat])
View this search on PubMed - 10US Food and Drug Administration. Approved prescribing information for tesamorelin acetate; label version 29 July 2026. Retrieved via openFDA drug/label.
- 11Semenistaya E, Zvereva I, Thomas A, Thevis M, Krotov G, Rodchenkov G. Drug Test Anal. 2015;7(10):919-25. doi:10.1002/dta.1787. PMID 25869809. Anti-doping laboratory study.
- 12US Food and Drug Administration, Center for Drug Evaluation and Research. Briefing document, 29 October 2024, section on clinical studies assessing safety. Regulatory document, not peer-reviewed. fda.gov

Reviewed for scientific accuracy
Dr. Martina Rossi, PhD
PhD, Université Grenoble Alpes · Scientific Contributor and Reviewer
Dr. Rossi's doctoral research at Université Grenoble Alpes examined the vascular functions of bone morphogenetic proteins. Her peer-reviewed work spans cell and molecular biology, vascular biology, and gene therapy, in journals including Cardiovascular Research, Scientific Reports, and Brain Sciences. She reviews Pure Peptides' product, reference, and research pages for scientific accuracy against the sources they cite.
Related comparisons
AOD-9604 vs Tesamorelin
AOD-9604 is a modified 16-residue peptide from the C-terminal end of human growth hormone; Tesamorelin is a 44-residue analog of human GHRH.
Read ComparisonCJC-1295 (No DAC) vs Ipamorelin
CJC-1295 (No DAC) is a synthetic peptide built on human GHRH's first 29 residues; Ipamorelin is a synthetic five-residue peptide.
Read ComparisonCJC-1295 (No DAC) vs Tesamorelin
CJC-1295 (No DAC) carries four substitutions in human GHRH's first 29 residues; Tesamorelin is an analog of the full 44-residue hormone.
Read Comparison

